Article Details

Ascletis Pharma's ASC30 oral tablet shows promise in obesity trial - Clinical Trials Arena

Retrieved on: 2025-01-21 16:51:00

Tags for this article:

Click the tags to see associated articles and topics

Ascletis Pharma's ASC30 oral tablet shows promise in obesity trial - Clinical Trials Arena. View article details on hiswai:

Excerpt

The gold standard of business intelligence. ... Up to 60 hours of long half-life and dose-proportional pharmacokinetics (PK) were demonstrated by the ...

Article found on: www.clinicaltrialsarena.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo